ONC releases long-awaited interoperability roadmap

Laura Pedulli | | Health Exec | Digital Transformation

The Office of the National Coordinator for Health Information Technology (ONC) has unveiled its highly-anticipated roadmap for interoperability, reports Clinical Innovation + Technology. 

The 166-page roadmap, “Connecting Health and Care for the Nation: A Shared Nationwide Interoperability Roadmap Version 1.0.,” builds on the June 2014 vision paper that outlines ONC's 10-year vision for an interoperable health IT infrastructure. It culminates from months of discussions with hundreds of stakeholders, as well as ONC advisory group feedback, listening sessions and an online forum, according to the story.

Read more below:

ONC unveils interoperability roadmap, first-ever standards advisory

Laura Pedulli

Related Content

From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI
Healthcare-specific AI: How to multiply successes and head off accidents

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.